Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liwanli Innovation CoTPE:3054 +1.75%58 5-Year Yield-on-Cost % is 1.65 as of Aug. 05, 2026, which is at its 10-year median of 1.65. GuruFocus rates TPE:3054 with a GF Score™ of 58/100 and a GF Value™ of NT$118.58 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 514 Drug Manufacturers companies, Liwanli Innovation Co ranks worse than 59.53% on this metric.
Liwanli Innovation Co's yield on cost for the quarter that ended in Jun. 2026 was 1.65.
The historical rank and industry rank for Liwanli Innovation Co's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:3054'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.5 Med: 1.65 Max: 2.73
Current: 1.65
During the past 13 years, Liwanli Innovation Co's highest Yield on Cost was 2.73. The lowest was 0.50. And the median was 1.65.
TPE:3054's 5-Year Yield-on-Cost % is ranked worse than 59.53% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.355
vs TPE:3054: 1.65
Liwanli Innovation Co (TPE:3054) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Liwanli Innovation Co 5-Year Yield-on-Cost % Related Terms
TPE:3054 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's 5-Year Yield-on-Cost % falls into.
Liwanli Innovation Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Liwanli Innovation Co (TPE:3054) has a 5-Year Yield-on-Cost % of 1.65 as of Aug. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Liwanli Innovation Co and its competitors. This is near median its historical median of 1.65. Over the past decade, Liwanli Innovation Co's 5-Year Yield-on-Cost % has ranged from 0.50 to 2.73. According to the industry distribution chart, Liwanli Innovation Co ranks #306 out of 514 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is Liwanli Innovation Co's 5-Year Yield-on-Cost % too high?
Liwanli Innovation Co's current 5-Year Yield-on-Cost % of 1.65 is near median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2.73. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Liwanli Innovation Co's value of 1.65 is 29.9% below this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #306 out of 514 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Liwanli Innovation Co has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #306 out of 514 companies for 5-Year Yield-on-Cost %. This places Liwanli Innovation Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Liwanli Innovation Co's value of 1.65 is 29.9% below this benchmark. Historically, Liwanli Innovation Co's own 5-Year Yield-on-Cost % has ranged from 0.50 to 2.73 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 2.36, Liwanli Innovation Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current 5-Year Yield-on-Cost % of 1.65 is 29.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current 5-Year Yield-on-Cost % is 1.65, which is near median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$118.58, compared to a current price of NT$49.30 — trading 58.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.65, which is near median its 10-year median of 1.65 and 29.9% below the Drug Manufacturers industry median of 2.36. Liwanli Innovation Co's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current 5-Year Yield-on-Cost % is 1.65 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$49.30 is trading 58.4% below its estimated GF Value™ of NT$118.58.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
5-Year Yield-on-Cost %: 1.65 (near median its 10-year median of 1.65)
GF Value™: NT$118.58 vs. price of NT$49.30 (58.4% below fair value)
Industry Position: 29.9% below the Drug Manufacturers median (#306 of 514)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
58GF Score
Get the complete analysis for TPE:3054
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
